A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Evaluate the Efficacy of Armodafinil for Patients With B-cell Lymphoma and Severe Fatigue Undergoing Standard R-CHOP Chemotherapy or in Remission Following Chemo and/or Radiation
Aims will be analyzed separately as stratified by treatment arm (chemotherapy treatment arm
vs. post-treatment remission arm).
Primary Objective:
- To determine whether armodafinil is more effective than placebo in reducing fatigue as
measured by the change in scores from the FACT-Fatigue reported at study entry, week 7
of study treatment, and study completion (week 13).
Secondary Objectives:
- To determine whether armodafinil is more effective than placebo in reducing fatigue as
measured by standard actigraphy summary statistics including total sleep time (TST),
wake after sleep onset (WASO), sleep latency, number of awakenings, daytime sleep time,
mean daytime activity, peak activity, acrophase, and circadian mesor at week 1 of
screening, week 7 of study treatment, and study completion (week 13).
- To determine whether armodafinil is more effective than placebo in improving work
quality as measured by the change in scores from the WLQ© reported at study entry
(week 1) and study completion (week 13).
- To determine whether armodafinil is more effective than placebo in reducing fatigue as
measured by the change in activity patterns with actigraphy using applied functional
data analysis during week 1 of screening, week 7 of study treatment, and study
completion (week 13).
- To evaluate whether measured cytokines (IL-2, IL-6, IL-10, TNF-α, and TGF-α) are
elevated at baseline.
- To evaluate whether measured cytokines (IL-2, IL-6, IL-10, TNF-α, and TGF-α) change
from the time of study entry to study completion.
- To assess whether cytokine levels (IL-2, IL-6, IL-10, TNF-α, and TGF-α) correlate with
circadian patterns in wrist actigraphy and self-described reports of fatigue as
measured by the FACT-Fatigue at baseline and study completion.
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
To determine whether armodafinil is more effective than placebo in reducing fatigue as measured by the change in scores from the FACT-Fatigue reported at study entry, week 7 of study treatment, and study completion (week 13).
13 weeks
No
Nina Wagner-Johnston, M
Principal Investigator
Washington University School of Medicine
United States: Institutional Review Board
09-1896
NCT01044004
March 2010
June 2012
Name | Location |
---|